The experimental vaccine, mRNA-1273, was well-tolerated in this older age group.

Tuesday, September 29, 2020 Investigational COVID-19 Vaccine Well-Tolerated and Generates Immune Response in Older Adults A paper published today in the New England Journal of Medicine describes some of the findings from a Phase 1 trial of an investigational mRNA vaccine. The study, which was supported by NIAID, began in March and was expanded to enroll older adults about one month later. The mRNA-1273 vaccine appears to be well-tolerated and generates a strong immune response in older adults. In general, older adults are more vulnerable to complications of COVID-19, and understanding how the vaccine affects older adults is a critical part of testing its safety and efficacy. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107